Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATOS 
Atossa Genetics Inc (ATOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/07/2025: ATOS (3-star) is a SELL. SELL since 4 days. Profits (-11.70%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.62
1 Year Target Price $5.62
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.54% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.98M USD | Price to earnings Ratio - | 1Y Target Price 5.62 |
Price to earnings Ratio - | 1Y Target Price 5.62 | ||
Volume (30-day avg) 4 | Beta 0.92 | 52 Weeks Range 0.55 - 1.66 | Updated Date 08/6/2025 |
52 Weeks Range 0.55 - 1.66 | Updated Date 08/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.67% | Return on Equity (TTM) -34.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38865853 | Price to Sales(TTM) - |
Enterprise Value 38865853 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 2.01 | Shares Outstanding 129170000 | Shares Floating 129098960 |
Shares Outstanding 129170000 | Shares Floating 129098960 | ||
Percent Insiders 0.07 | Percent Institutions 28.11 |
Upturn AI SWOT
Atossa Genetics Inc
Company Overview
History and Background
Atossa Therapeutics, Inc. was originally incorporated in 2009. It focuses on developing innovative medicines in areas of significant unmet medical need in breast cancer and other cancers. They have transitioned over time, focusing increasingly on proprietary drug development.
Core Business Areas
- Drug Development: Focuses on developing proprietary pharmaceuticals and diagnostic products for breast cancer and other oncological diseases. This includes clinical trials and regulatory approval processes.
- Proprietary Pharmaceuticals: Involves the research, development, and potential commercialization of their proprietary drugs such as (Z)-endoxifen.
Leadership and Structure
Dr. Steven Quay is the President and CEO. The company has a typical board structure with committees focused on audit, compensation, and governance.
Top Products and Market Share
Key Offerings
- (Z)-endoxifen: Atossa's lead drug candidate, (Z)-endoxifen, is being developed for the treatment of breast cancer. Market share data is not publicly available as it is still in development. Competitors include established breast cancer therapies from companies like Novartis, AstraZeneca, and Pfizer.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the oncology segment, is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Significant innovation and unmet needs create potential for new entrants.
Positioning
Atossa is a clinical-stage biopharmaceutical company focused on innovative approaches to breast cancer treatment. Their competitive advantage lies in their novel drug candidates and targeted approach. However, they compete with larger, more established pharmaceutical companies.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is expected to reach billions of dollars annually. Atossa aims to capture a portion of this market with its (Z)-endoxifen and other pipeline products. Specific TAM figures vary based on indication and geography.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Experienced leadership team
- Focus on unmet medical needs in breast cancer
- Early clinical trial success
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- No currently marketed products
- High risk of clinical trial failure
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
- Advancements in personalized medicine
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- NVS
- AZN
- PFE
- GILD
Competitive Landscape
Atossa operates in a competitive landscape dominated by large pharmaceutical companies. Their advantage lies in their innovative approach, but they face challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D investment and operating losses as the company advances its clinical pipeline.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary based on these factors. Analyst Revenue Projection: [5, 25, 100, 250, 500](USD Millions).
Recent Initiatives: Recent initiatives include advancing clinical trials for (Z)-endoxifen and other pipeline products, as well as seeking strategic partnerships.
Summary
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on breast cancer treatments. Its success heavily relies on its (Z)-endoxifen clinical trial results. The company operates with significant operating losses, but potential partnerships can help strengthen its growth. Investors should watch for the outcome of clinical trials, competition, and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimation and may not reflect real-time values.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atossa Genetics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2012-11-08 | Chairman, CEO & President Dr. Steven C. Quay FCAP, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.